• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Clinical management of hepatitis B virus infection correlated with liver transplantation

    2010-06-29 10:12:16JianZhangLinZhouandShuSenZheng

    Jian Zhang, Lin Zhou and Shu-Sen Zheng

    Hangzhou, China

    Clinical management of hepatitis B virus infection correlated with liver transplantation

    Jian Zhang, Lin Zhou and Shu-Sen Zheng

    Hangzhou, China

    BACKGROUND:As a radical cure for post-hepatitis B virus (HBV)-related liver cirrhosis and hepatocellular carcinoma, liver transplantation has been applied in many medical centers. Before the use of effective measures, hepatitis B recurrence and the existence of HBsAg(+) donors, patients with hepatitis B-related diseases are contraindicated for liver transplantation. Application of interferon, hepatitis B immunoglobulin (HBIG), and nucleotide analogues (e.g., lamivudine) has made great progress in the clinical care of HBV. However, there are still many shortcomings such as low viral suppression rate, rising expense, and the induction of HBV tyrosine-methionineaspartate-aspartate (YMDD) mutation. This article systematically reviews the current evidence that immunotherapy, conventional drug combinations, and some special fields of HBV infection correlate with liver transplantation.

    DATA SOURCES:Studies were identified by searching MEDLINE and PubMed for articles using the keywords "hepatitis B virus", "hepatitis B vaccination", "lamivudine", "adefovir", "entecavir", "tenofovir", "HBV genotype", and "liver transplantation" up to October 2009. Additional papers were identified by a manual search of the references from the key articles.

    RESULTS:Hepatitis B vaccine and human monoclonal antibody have very good clinical prospects. Compared with traditional therapies, the new medical regimens have many benefits such as boosting viral suppression rate and decreasing medical expenses. The triple therapy for YMDD mutation also has an excellent therapeutic effect and a low barrier to resistance. New nucleos(t)ide analogues (entecavir and tenofovir) eliminate virus more effectively with few adverse reactions, and may replace lamivudine or HBIG in future.CONCLUSIONS:Hepatitis B vaccine needs further largescale and rigorous randomized controlled trials to confirm its effective dose and injection frequency. Monoclonal antibody is still experimental, and the next step is to carry out the relevant animal and human studies. A consensus standard regimen for the treatment of hepatitis B should be developed.

    (Hepatobiliary Pancreat Dis Int 2010; 9: 15-21)

    hepatitis B vaccination;hepatitis B immunoglobulin; lamivudine; liver transplantation; adefovir; hepatitis B virus; genotype

    Introduction

    Hepatitis B is a viral infection that attacks the liver and can cause both acute and chronic diseases. About 2 billion people worldwide have been infected with the virus and about 350 million live with chronic infection. An estimated number of 600 000 persons die each year from the acute or chronic consequences of hepatitis B.

    Liver transplantation is a radical cure for posthepatitis B virus (HBV)-related cirrhosis and hepatocellular carcinoma. In Japan, the morbidity of post-HBV-related liver cirrhosis is about 13.9%.[1]In China, HBV related diseases is the most common primary reason for liver transplantation (78.6%).[2]Although liver transplantation can alleviate clinical symptoms such as ascites, hepatic encephalopathy, hypoalbuminemia, and infection, the adverse effects of immunosuppressive drugs raise the possibility of HBV recurrence or virus breakthrough.[3]Choosing the right prophylactic drug to control the HBV DNA load at an acceptable level is very important.

    Immunotherapy is a promising treatment that can enhance the body's ability to resist viruses. Traditional non-specific immune therapy is a passive one such as HBIG. Then studies have been concentrated onthe specific immune therapy for stimulating active immunity-vaccines. The development of new vaccines that stimulate an effective immune response when patients receive an organ transplant is a hot topic. Recently, Pan et al[4]synthesized engineered mAbs that showed inhibition of HBVin vitro.

    Various monotherapies and combinations have been developed for the treatment of hepatitis B.[5,6]These drugs have played important therapeutic roles, and they also have inherent disadvantages such as adverse reactions, hepatitis B recurrence, and long-term drugresistant strains. Viral resistance mechanisms and the pharmacoeconomics of combination therapy have been reported.[7]

    Immunotherapy

    Hepatitis B vaccination: dose and phase?

    Inducing an active immune response against the hepatitis B surface antigen (HBsAg) leads to continuous secretion of specific antibodies. The vaccine is given in either three or four separate doses as part of the existing routine immunization schedule. The safe anti-HBs titer for continuous prevention of HBV reinfection varies in some studies. Relatively low seroconversion rates and serum anti-HBs concentrations are reported among chronic HBV-infected liver transplantation recipients; only a minority of vaccines may have stable antibody levels >100 IU/L.[8]In the past, anti-HBs-positive individuals (seropositivity: anti-HBs titer of >10 IU/L) have always been considered safe to receive orthotopic liver transplantation for non-HBV-related diseases. Five of ninede novoHBV-infected patients were anti-HBs positive before orthotopic liver transplantation.[9]So, for prevention ofde novoHBV infection after transplantation, the protective anti-HBs titer should be >200 IU/L.[10]

    It has been reported that the response rate to HBV vaccine is significantly lower in patients with liver cirrhosis, immunocompromised patients, or organ transplant recipients.[8]When discussing immune status including T-cell and B-cell activity with response rate, Tahara et al[11]found that T-cell interactions which lead to an effective immune response to hepatitis B vaccination can cause activation of anti-HBsAg-specific T cells and suppression of anti-donor-specific T cells. Patients showing a donor-specific hyporesponse with a well-maintained response to a third-party (exogenous) stimulus always have a sustained immune response to the vaccine. Another study on T-cell immunity found that in 12 orthotopic liver transplantation recipients with HBV recurrence, the HBV-specific T-cell immunity was enhanced to a level comparable to that of patients with chronic hepatitis B, and the level was dependent on the serum viral load. Thus this raises an interesting question whether the higher response in theresearch of Tahara et al is really due to the donor-specific hyporesponse or just to the activity of anti-HBsAgspecific T cells or both. Schumann et al[12]demonstrated that HBV-specific humoral and cellular immunity can be transferred by liver transplantation after vaccination of the donor. The transfer of B-cell and T-cell immunity correlates with the magnitude of the immune responses in the donor.

    Table. Comparison of four studies of hepatitis B vaccination

    The response rate of liver transplantation candidates (with HBV-unrelated liver failure) to recombinant hepatitis B vaccination varies from 16% to 62%.[13]Many variables are associated with the response rate, the most important being the injection frequency and dose per injection. The Table shows four different studies of hepatitis B vaccination. Although these studies may be incompletely randomized or lack proper controls they show that 3-4 doses (40 μg), which can stimulate the necessarily response rate (30%-41%), are optimal for vaccination. But the HBsAb titer of responders varies a lot. Larger randomized controlled trials with good quality controls and design will provide more distinct answers about the dose, phase and response rate of hepatitis B vaccination.

    In special patients, the existing routine immunization schedules may not be equally effective as in normal people. Yamashiki et al[14]investigated 18 patients who underwent liver transplantation for chronic hepatitis B and 2 non-HBV-infected patients who received hepatitis B core antibody (HBcAb)-positive donor organs; doubledose double-phase use of second-generation recombinant vaccine was not effective in preventing hepatitis B recurrence in the study population. These populations should be targeted for a conventional vaccine regimen, and different approaches such as strong adjuvant or pre-S containing protein should be further tested.

    Vaccination also shows differences in sex, both in adult and pediatric liver transplantation groups. Girls respond with higher anti-HBs titres than boys, as do women.[18,19]It has become an interesting controversy whether the treatment is individualized to different ethnicities or groups of people. Ni et al[19]found that more than half of the children who were primarily vaccinated with HBV vaccines maintained adequate anti-HBs titers 1 year later after liver transplantation. All consecutive patients maintain a certain degree of cellular immune response irrespective of their anti-HBs status after liver transplantation. We expect that one or more doses of booster may help children who receive transplantation to develop protective response to anti-HBs.

    Human mAb: a novel approach?

    High specificity monoclonal antibodies to pathogens such as human papilloma virus have greatly expanded therapeutic methodology. Genetically engineered mAbs specific to the surface antigens of HBV would be a good alternative for the immunoprophylaxis of HBV infection.[20]Thus Pan et al[4]cloned the gene of a high Fab-affinity antibody from human peripheral blood and constructed Fab antibody rAAV-HB. After evaluating the activity of antibody hepatitis B in tree shrews treated with intramuscular injection of rAAV-HB andin vitroexperiments, they concluded that human antibody will be useful for the immunoprophylaxis of HBV infection, but this needs further study in human experiments. The safety and efficiency of transgenic drugs is controversial, which may restrict the use of engineered monoclonal antibodies.

    Drug regimens

    HBIG and lamivudine combination: low-dose intramuscular or high-dose intravenous HBIG?

    The HBIG (10 000 IU per month) and lamivudine regimen used to be the gold standard for prophylaxis against HBV recurrence after liver transplant. This therapy reduces the risk of recurrence to less than 5% at 5 years.[21]However, the cost of HBIG has driven people to investigate a lowdose of intramuscular HBIG (400-800 IU per month) and lamivudine in combination. This combination can achieve the same prophylaxis effect at a lower cost.[22]In Tashiro's research,[23]although two patients were preoperatively HBV DNA-positive shown by a transcription-mediated amplification assay method, all 14 patients receiving a high dose (10 000 IU/day) of HBIG and lamivudine in combination postoperatively became HBV-DNA-negative and HBsAg-negative.

    In Chinese liver transplant patients, the efficacy of HBIG was found to be associated with human leukocyte Fcγ receptor 3A gene polymorphisms (at nucleotide site 559). Among the 559G carrier group (n=42, 54.5%), the risk of HBV recurrence was 9.5%, and the 1- and 2-year recurrence-free survival rates were 95.2% and 88.7%, respectively. In the 559G noncarrier group (n=35, 45.5%), the risk of HBV recurrence was 28.6%, and the 1-and 2-year recurrence-free survival rates were 74.3% and 69.3%. Detecting FCGR3A genotypes can be a clinical reference for treatment before HBIG administration.[24]

    Hooman et al[25]pointed out that administration of intravenous HBIG (2000 IU per six weeks) and intramuscular administration of HBIG (2000 IU per six weeks) are equally effective with antibody against hepatitis B surface antigen (anti-HBs) in pharmacokinetics. Intramuscular HBIG may not be dose-saving; however, it may be cost-effective if the price per unit of intramuscular HBIG is lower. Individualized dosing intervals should be further evaluated as a cost-effective alternative to fixed dose schemes.

    Saab et al[26]compared prophylaxis with lamivudine and adefovir (strategy 1), with intramuscular HBIG and lamivudine (strategy 2) with the addition of adefovir in patients who subsequently developed hepatitis B recurrence. The medical costs for strategies 1 and 2 after 10 years of therapy were $151819 and $166246, respectively, and the cost saving was $14427. They developed a Markov model to provide pharmacoeconomic support for the use of strategy 1 as first-line therapy in hepatitis B prophylaxis in liver transplant recipients 1 year after transplantation. Strategy 1 not only decreased the total fee for preventing hepatitis B after liver transplantation, but also improved the quality of life. Administration of HBIG requires frequent blood tests to assess antibody titers. On the other hand, adefovir is an oral medication with rare adverse effects and less demand for frequent monitoring.

    High-dose HBIG during the ahepatic period and in the early stage of post transplantation can fulfill the treatment target as a long-term lamivudine therapy before liver transplantation. Long-term preoperative lamivudine treatment may result in an earlier HBV mutation in YMDD and increase the HBV recurrence rate and risk in the first year after transplantation.[27]Yilmaz et al[28]found that recurrence can be prevented in E-antigen-negative patients with HBIG alone or in E-antigen-positive patients with a combination of HBIG and an anti-viral agent. Eight out of fifteen E-antigen-positive patients who received HBIG alone developed recurrence after a mean of 17 months. As long as the anti-HBV surface remained detectable, no absolute minimum serum level appeared to lead to recurrent HBV. But the question is raised whether this combination or use of HBIG alone should be continued within 1 year after operation.

    Polyvalent immunoglobulin can cause nephrotoxicity. Pathologic examination of the kidneys generally reveals changes typical of osmotic nephrosis. The inappropriate use of HBIG can increase the risk of renal dysfunction, particularly in combination with nephrotoxic drugs.[29]

    Lamivudine and adefovir dipivoxil regimen: effective and easy to get

    Lamivudine and adefovir represent two different classes of anti-HBV agents (L-nucleoside and acyclic phosphonate) with different mechanisms of action, and there is no cross-resistance between them. Their combination greatly reduces the risk of subsequent adefovir resistance in nontransplantation patients.[30]Prophylaxis combined with adefovir/lamivudine therapy without the use of long-term HBIG is effective and well tolerated.[31]Meanwhile we cannot exclude the possibility that with a prolonged follow-up, some patients may experience viral breakthrough due to the appearance of lamivudine/adefovir resistance.[5]

    Before liver transplantation, lamivudine was proposed to be down-graded from the first to second-line therapy. In contrast, adefovir dipivoxil has been approved not only as the first-line therapy but also as rescue therapy for patients with lamivudine resistance.[32]A retrospective cohort study evaluated the safety and efficacy of adefovir in 68 elderly and cirrhotic patients with lamivudine-resistant chronic hepatitis B, among whom 75.4% received a combination treatment with lamivudine and adefovir for a median duration of 12.6 months; the remaining patients received adefovir overlapping with lamivudine treatment for a median duration of 7.9 months. At the end of the follow-up, 41.2% of the patients had undetectable HBV DNA (≤2000 copies/ml) with a median reduction of lg3.4 copies/ ml. No resistance mutations and no significant side effects were observed.[33]Even though no combination treatment can cover all the possible mutation strains, we focus on reducing the resistance as much as possible to get a good prognosis.

    A seven-year follow-up study of 24 patients showed that HBV recurrence developed in 7 patients with cumulative probabilities of 8%, 13%, 28%, 35%, 35%, and 49% in 1, 2, 3, 4, 5, and 6 years. Four patients had rtM204I mutation, and in 3 of them HBV DNA levels were too low for sequencing. After use of lamivudine followed by adefovir salvage for 150 weeks (91-193), 6 (86%) patients had normal ALT levels. HBV DNA was undetected in 2 (29%) patients, 100-1000 copies/ml in 2 (29%) and 10 000-100 000 copies/ml in 3 (43%) on the last visit. No genotypic resistance to adefovir was detected,[34]showing that lamivudine followed by adefovir salvage is effective for prophylaxis of recurrence of HBV for up to 7 years after liver transplantation.

    Management of YMDD mutant: lamivudine, adefovir and HBIG triple therapy

    YMDD mutation is common in the application of lamivudine in treating HBV. In 183 adult liver transplantation patients who lived more than 6 months and were followed up for 14.6 months, the rate of YMDD mutation in the lamivudine group was 8.49% (9/106), markedly higher than that in the lamivudine+HBIG group (1.30%, 1/77;P=0.035). The patients with YMDDmutation improved after treatment with adefovir.[35]

    4.烤箱預(yù)熱至160度,取烤盤、上置一烤架,雞置于烤架上(雞背向上),烤盤置于烤箱最下層,烘烤時(shí)間為每1000克雞烤35-40分鐘。每過45分鐘將烤盤中的湯汁和雞油,收集起來倒在另一盆內(nèi)。同時(shí)將雞翻一次身。

    In patients with YMDD mutation at the time of transplantation, combined use of HBIG and lamivudine is not consistently successful in preventing reinfection. In this situation, the addition of another antiviral agent combating the drug-resistant virus (i.e., adefovir, tenofovir, or entecavir) would be expected to further reduce the risk of prophylaxis failure.[36]

    As described in a ten-year study from Ikegami et al,[37]patients with YMDD mutation (9 of 29 patients), except an HBsAg-positive donor, were successfully protected by the triple therapy of lamivudine, adefovir, and HBIG. No graft loss was due to the recurrence of HBV. YMDD mutation should be closely monitored during lamivudine treatment.[38]

    Other oral nucleos(t)ide analogues: entecavir and tenofovir

    Entecavir is a guanosine nucleotide analogue. It is a new, highly potent antiviral agent; phase Ⅱ and Ⅲstudies have demonstrated this drug to be superior to placebo and lamivudine in patients with chronic HBV.[39]Because of the low resistance barrier, it used to be a substitute for lamivudine-resistant patients. Kurashige et al[40]recommended that lamivudine-to-entecavir switching treatment may be suitable in chronic hepatitis B patients without evidence of lamivudine resistance during the preceding lamivudine treatment with great attention to the emergence of entecavir-resistance.

    Kamar et al[41]reported that 10 male transplant patients with chronic HBV infection who were adefovir-(n=9) or lamivudine-resistant (n=1) were given entecavir at 0.5 to 1 mg/d. All patients were HBsAg-positive. After a median follow-up of 16.5 months, entecavir therapy reduced the HBV DNA viral load from lg3.86 (lg2.71-lg6.46) copies/ml at baseline to lg2.94 (lg2.15-lg4) copies/ml at the last follow-up (P=0.004). The host biological response was better in kidney transplant patients than in liver transplant patients because HBV has a liver tropism which may be more resistant and more aggressive in a transplanted liver than in a native one.[41]This study showed good results of entecavir in treating kidney or liver transplant patients, which may be used in treatment of liver-kidney transplantation patients.

    Tenofovir is an acyclic nucleotide analog, reverse transcriptase inhibitor.[42]Zhu et al[43]compared different regimens of tenofovir with lamivudine, entecavir, and adefovir. They found that of combinations lamivudine+tenofovir, entecavir+tenofovir, and adefovir+ tenofovir showed additive anti-HBV effectsin vitro. This supports the use of tenofovir as a component in combination regimens with currently available anti-HBV nucleoside analogues.

    Benefits and risks of combination therapy

    Many reports describe the benefits and risks of hepatitis B drug treatment. This section just mentions some special points of liver transplantation. Combination therapy for hepatitis B is recommended in specific patients: those who have undergone liver transplantation, those with decompensated cirrhosis, those coinfected with human immunodeficiency virus and HBV who are on antiretroviral therapy, and those with drug-resistant HBV infection.[44]In successful antiviral combination therapy, different drug regimens may cover major virus mutation pathways to minimize possible drug resistance. However, investigators still find many different mutations in response to the first line drugs such as lamivudine with rtM204V, rtL180M, and rtS202G mutations.[40]These mutations may cause virus recurrence and lead to transplant failure. Thus it is important to monitor the status of patients during therapy. Monitoring of treatment response includes tests for serum aminotransferase level, HBV DNA level, hepatitis B e antigen (HBeAg) and antibody (anti-HBe), hepatitis B surface antigen (HBsAg) or antibody (anti-HBs), and liver histology.[45]Early discovery of possible drug resistance may contribute to a good prognosis of liver transplantation.

    Genetic factors and drug therapy: individual treatment

    Eight distinct genotypes of HBV A to H have been identified, each having a characteristic geographic distribution.[46,47]Each genotype can be divided into many subtypes like B1-B4, and C1-C4. In China, B2 and C2 predominate.[48]Genotype can effect graft survival rate and the cumulative rate of viral breakthrough. Lo et al[49]found that genotype B patients have more pre-transplant acute flare, poorer liver functions, and higher end-stage liver disease scores. Fewer genotype B patients have HBeAg (13% vs. 32%;P=0.017). The 3-year graft survival rate is 83% for genotype B and 89% for genotype C (P=0.2). The graft survival due to lamivudine-resistant mutation at 3 years is 4% for genotype B and 21% for genotype C (P=0.017). Liver biopsy after viral breakthrough showed recurrent hepatitis B in 7 of 10 genotype C patients.

    Gene polymorphism also contributes to host immune behavior to HBV and drugs, such as mutations of the gene coding for the major hydrophilic region of HBsAg may be associated with anti-HBs immunoglobulins or vaccine escape.[50]In Chinese liver transplantation, the organ recipients with CTLA-4 +49 GG genotype have a reduced risk (6.67%,n=11) of HBV recurrence comparedwith non-CTLA-4 +49 GG-carrying individuals (20.7%) (relative risk 3.098;P=0.032).[51]

    After ending of the human genome project, the concept of molecular medicine has emerged. The evidence mentioned above can lead to early diagnosis and genetic prediction of HBV infection or recurrence. Before prescribing a drug in future we may review the genetic characteristics of a patient and decide the best choice of therapy.

    In conclusion, further research is needed to provide evidence-based recommendations about optimal antiviral therapy in adults with chronic hepatitis B infection. Monoclonal antibodies are still in the experimental stage, and the next step is taken to do relevant animal and human studies. A consensus on a standard regimen for the treatment of hepatitis B should be achieved.

    Funding:This study was supported by grants from the Key Program of National Natural Science Foundation of China (30730085) and the National High Technology Research and Development Program of China (863 Program; 2006AA 02A412).

    Ethical approval:Not needed.

    Contributors:ZJ wrote the main body of the article under the supervision of ZL and ZSS. ZL and ZSS provided advice on medical aspects. ZSS is the guarantor.

    Competing interest:No bene fits in any form have been received or will be received from a commercial party related directly or indirectly to the subject of this article.

    1 Michitaka K, Nishiguchi S, Aoyagi Y, Hiasa Y, Tokumoto Y, Onji M, et al. Etiology of liver cirrhosis in Japan: a nationwide survey. J Gastroenterol 2009.

    2 Zhao J, Yan L, Li B, Zeng Y, Wen T, Zhao J, et al. Diabetes mellitus after living donor liver transplantation: data from mainland China. Transplant Proc 2009;41:1756-1760.

    3 Lok AS. How to diagnose and treat hepatitis B virus antiviral drug resistance in the liver transplant setting. Liver Transpl 2008;14:S8-S14.

    4 Pan T, Cai M, Tang L, Zhou LQ, Li BJ, Zhu T, et al. A novel approach of prophylaxis to HBV recurrence after liver transplantation. Virology 2008;382:1-9.

    5 Angus PW, Patterson SJ, Strasser SI, McCaughan GW, Gane E. A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis. Hepatology 2008;48:1460-1466.

    6 Zhang FK, Zhang Y, Zhang JY, Jia JD, Wang BE. Favorable outcome of de novo hepatitis B infection after liver transplantation with lamivudine and adefovir therapy. Transpl Infect Dis 2009;11:549-552.

    7 Avolio AW, Nure E, Pompili M, Barbarino R, Basso M, Caccamo L, et al. Liver transplantation for hepatitis B virus patients: long-term results of three therapeutic approaches. Transplant Proc 2008;40:1961-1964.

    8 Castells L, Esteban R. Hepatitis B vaccination in liver transplant candidates. Eur J Gastroenterol Hepatol 2001;13:359-361.

    9 Bárcena Marugán R, García-Hoz F, Vázquez Romero M, Nash R, Mateos M, González Alonso R, et al. Prevention of de novo hepatitis B infection in liver allograft recipients with previous hepatitis B infection or hepatitis B vaccination. Am J Gastroenterol 2002;97:2398-2401.

    10 Su WJ, Ho MC, Ni YH, Chen HL, Hu RH, Wu YM, et al. High-titer antibody to hepatitis B surface antigen before liver transplantation can prevent de novo hepatitis B infection. J Pediatr Gastroenterol Nutr 2009;48:203-208.

    11 Tahara H, Tanaka Y, Ishiyama K, Ide K, Shishida M, Irei T, et al. Successful hepatitis B vaccination in liver transplant recipients with donor-specific hyporesponsiveness. Transpl Int 2009;22: 805-813.

    12 Schumann A, Lindemann M, Valentin-Gamazo C, Lu M, Elmaagacli A, Dahmen U, et al. Adoptive immune transfer of hepatitis B virus specific immunity from immunized living liver donors to liver recipients. Transplantation 2009;87:103-111.

    13 Takemura N, Sugawara Y, Tamura S, Makuuchi M. Liver transplantation using hepatitis B core antibody-positive grafts: review and university of Tokyo experience. Dig Dis Sci 2007; 52:2472-2477.

    14 Yamashiki N, Sugawara Y, Tamura S, Kaneko J, Matsui Y, Togashi J, et al. Double-dose double-phase use of second generation hepatitis B virus vaccine in patients after living donor liver transplantation: Not an effective measure in transplant recipients. Hepatol Res 2009;39:7-13.

    15 Pascasio JM, AoufiS, Gash A, Sousa JM, Perea R, Sayago M, et al. Response to a vaccination schedule with 4 doses of 40 microg against hepatitis B virus in cirrhotic patients evaluated for liver transplantation. Transplant Proc 2008;40:2943-2945.

    16 Bonazzi PR, Bacchella T, Freitas AC, Osaki KT, Lopes MH, Freire MP, et al. Double-dose hepatitis B vaccination in cirrhotic patients on a liver transplant waiting list. Braz J Infect Dis 2008;12:306-309.

    17 Jin SJ, Lu SC, Lai W, Dai J, Zhao J, Li YP, et al. Enhancing active immunity against hepatitis B virus by HBV vaccine immunization in patients with HBV-related end-stage liver diseases treated with liver transplantation. Zhonghua Gan Zang Bing Za Zhi 2008;16:261-264.

    18 Fang JW, Lai CL, Chung HT, Wu PC, Lau JY. Female children respond to recombinant hepatitis B vaccine with a higher titre than male. J Trop Pediatr 1994;40:104-107.

    19 Ni YH, Ho MC, Wu JF, Chen HL, Wu YM, Hu RH, et al. Response to booster hepatitis B vaccines in liver-transplanted children primarily vaccinated in infancy. Transplantation 2008;86:1531-1535.

    20 Hong HJ, Ryu CJ, Hur H, Kim S, Oh HK, Oh MS, et al. In vivo neutralization of hepatitis B virus infection by an anti-preS1 humanized antibody in chimpanzees. Virology 2004;318:134-141.

    21 Papatheodoridis GV, Cholongitas E, Archimandritis AJ, Burroughs AK. Current management of hepatitis B virus infection before and after liver transplantation. Liver Int 2009; 29:1294-1305.

    22 Angus PW, McCaughan GW, Gane EJ, Crawford DH, Harley H. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B. Liver Transpl 2000;6:429-433.

    23 Tashiro H, Itamoto T, Fudaba Y, Ohdan H, Fukuda S, KohashiT, et al. Prophylaxis against recurrence of HBV hepatitis after living-donor liver transplantation. Hepatogastroenterology 2008;55:1746-1749.

    24 Wang WL, Zhang GL, Wu LH, Yao MY, Jin J, Jia CK, et al. Efficacy of hepatitis B immunoglobulin in relation to the gene polymorphisms of human leukocyte Fcgamma receptor III (CD16) in Chinese liver transplant patients. Chin Med J (Engl) 2007;120:1606-1610.

    25 Hooman N, Rifai K, Hadem J, Vaske B, Philipp G, Priess A, et al. Antibody to hepatitis B surface antigen trough levels and half-lives do not differ after intravenous and intramuscular hepatitis B immunoglobulin administration after liver transplantation. Liver Transpl 2008;14:435-442.

    26 Saab S, Ham MY, Stone MA, Holt C, Tong M. Decision analysis model for hepatitis B prophylaxis one year after liver transplantation. Liver Transpl 2009;15:413-420.

    27 Lu AW, Zheng SS, Wu MP, Shen Y, Yang RW. Reevaluation of the effect of lamivudine therapy preoperative to prevent HBV recurrence after liver transplantation. Hepatobiliary Pancreat Dis Int 2008;7:357-361.

    28 Yilmaz N, Shiffman ML, Todd Stravitz R, Sterling RK, Luketic VA, Sanyal AJ, et al. Prophylaxsis against recurrance of hepatitis B virus after liver transplantation: a retrospective analysis spanning 20 years. Liver Int 2008;28:72-78.

    29 Angeli P, Scaglione F. Nephrotoxicity of intravenous immunoglobulin in the setting of liver transplantation or HBV-related cirrhosis: an undervalued topic. Minerva Gastroenterol Dietol 2008;54:259-275.

    30 Lampertico P, Viganò M, Manenti E, Iavarone M, Sablon E, Colombo M. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 2007;133:1445-1451.

    31 Patterson SJ, Angus PW. Post-liver transplant hepatitis B prophylaxis: the role of oral nucleos(t)ide analogues. Curr Opin Organ Transplant 2009;14:225-230.

    32 Jiang L, Jiang LS, Cheng NS, Yan LN. Current prophylactic strategies against hepatitis B virus recurrence after liver transplantation. World J Gastroenterol 2009;15:2489-2499.

    33 Zoulim F, Parvaz P, Marcellin P, Zarski JP, Beaugrand M, Benhamou Y, et al. Adefovir dipivoxil is effective for the treatment of cirrhotic patients with lamivudine failure. Liver Int 2009;29:420-426.

    34 Limquiaco JL, Wong J, Wong VW, Wong GL, Tse CH, Chan HY, et al. Lamivudine monoprophylaxis and adefovir salvage for liver transplantation in chronic hepatitis B: a seven-year follow-up study. J Med Virol 2009;81:224-229.

    35 Zhang XL, Zhu XF, Shi HJ, Cui SZ, Tang YQ, Ba MC, et al. Prevention and treatment of hepatitis B recurrence after liver transplantation. Zhonghua Yi Xue Za Zhi 2008;88:606-609.

    36 Samuel D. The option of liver transplantation for hepatitis B: where are we? Dig Liver Dis 2009;41:S185-189.

    37 Ikegami T, Soejima Y, Ohta R, Taketomi A, Yoshizumi T, Harada N, et al. Living donor liver transplantation for hepatitis B associated liver diseases: a 10-year experience in a single center. Hepatogastroenterology 2008;55:1445-1449.

    38 Gwak GY, Huh W, Lee DH, Choi MS, Lee JH, Koh KC, et al. The incidence and clinical outcome of YMDD mutants in hepatitis B surface antigen-positive renal allograft recipients after prolonged lamivudine therapy. Transplant Proc 2007;39: 3121-3126.

    39 Calleja JL, Penas B. Enferm Infecc Microbiol Clin 2008;26:S39-48.

    40 Kurashige N, Ohkawa K, Hiramatsu N, Yakushijin T, Mochizuki K, Oze T, et al. Lamivudine-to-entecavir switching treatment in type B chronic hepatitis patients without evidence of lamivudine resistance. J Gastroenterol 2009;44:864-870.

    41 Kamar N, Milioto O, Alric L, El Kahwaji L, Cointault O, Lavayssière L, et al. Entecavir therapy for adefovir-resistant hepatitis B virus infection in kidney and liver allograft recipients. Transplantation 2008;86:611-614.

    42 Reynaud L, Carleo MA, Talamo M, Borgia G. Tenofovir and its potential in the treatment of hepatitis B virus. Ther Clin Risk Manag 2009;5:177-185.

    43 Zhu Y, Curtis M, Qi X, Miller MD, Borroto-Esoda K. Antihepatitis B virus activity in vitro of combinations of tenofovir with nucleoside/nucleotide analogues. Antivir Chem Chemother 2009;19:165-176.

    44 Terrault NA. Benefits and risks of combination therapy for hepatitis B. Hepatology 2009;49:S122-128.

    45 Andersson KL, Chung RT. Monitoring during and after antiviral therapy for hepatitis B. Hepatology 2009;49:S166-173.

    46 Fung SK, Lok AS. Hepatitis B virus genotypes: do they play a role in the outcome of HBV infection? Hepatology 2004;40: 790-792.

    47 Echevarría JM, Avellón A. Hepatitis B virus genetic diversity. J Med Virol 2006;78:S36-42.

    48 Norder H, Couroucé AM, Coursaget P, Echevarria JM, Lee SD, Mushahwar IK, et al. Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes. Intervirology 2004;47:289-309.

    49 Lo CM, Cheung CK, Lau GK, Yuen MF, Liu CL, Chan SC, et al. Significance of hepatitis B virus genotype in liver transplantation for chronic hepatitis B. Am J Transplant 2005; 5:1893-1900.

    50 Roque-Afonso AM, Ferey MP, Belkhiri D, Dussaix E. HBs antigen mutants: prevalence, clinical and diagnostic implications. Pathol Biol (Paris) 2005;53:563-568.

    51 Jiang Z, Feng X, Zhang W, Gao F, Ling Q, Zhou L, et al. Recipient cytotoxic T lymphocyte antigen-4 +49 G/G genotype is associated with reduced incidence of hepatitis B virus recurrence after liver transplantation among Chinese patients. Liver Int 2007;27:1202-1208.

    October 22, 2009

    Accepted after revision December 23, 2009

    Author Affiliations: Key Laboratory of Combined Multi-Organ Transplantation, Ministry of Public Health; Key Laboratory of Organ Transplantation, Zhejiang Province; First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China (Zhang J, Zhouland Zheng SS)

    Shu-Sen Zheng, MD, PhD, FACS, Key Laboratory of Combined Multi-Organ Transplantation, Ministry of Public Health, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China (Tel: 86-571-87236601; Email: shusenzheng@zju.edu.cn)

    ? 2010, Hepatobiliary Pancreat Dis Int. All rights reserved.

    久久中文字幕一级| 中文字幕av在线有码专区| 777久久人妻少妇嫩草av网站| 此物有八面人人有两片| 九色成人免费人妻av| 中亚洲国语对白在线视频| 久久草成人影院| 久久 成人 亚洲| 久久久久久久久中文| 波多野结衣巨乳人妻| 可以免费在线观看a视频的电影网站| 亚洲欧洲精品一区二区精品久久久| 欧美中文综合在线视频| 黄片大片在线免费观看| 中文字幕最新亚洲高清| 国产亚洲精品久久久久久毛片| 国产高清激情床上av| 日韩欧美免费精品| 很黄的视频免费| 一级毛片精品| 此物有八面人人有两片| 日韩欧美免费精品| 亚洲av电影不卡..在线观看| 国产精品1区2区在线观看.| 美女免费视频网站| 欧美zozozo另类| 成人国语在线视频| 中文资源天堂在线| 日韩精品青青久久久久久| 欧美黑人欧美精品刺激| 最近在线观看免费完整版| 九色国产91popny在线| 变态另类成人亚洲欧美熟女| 国产精品免费一区二区三区在线| 久久午夜亚洲精品久久| 久久 成人 亚洲| 欧美一区二区精品小视频在线| 天堂动漫精品| 亚洲成人久久爱视频| 欧美一级a爱片免费观看看 | 一进一出抽搐动态| 国产亚洲精品av在线| 亚洲av成人不卡在线观看播放网| 国内毛片毛片毛片毛片毛片| 91麻豆av在线| av免费在线观看网站| 久久国产乱子伦精品免费另类| 亚洲无线在线观看| 三级毛片av免费| 一级毛片高清免费大全| 色在线成人网| 亚洲九九香蕉| 亚洲av电影不卡..在线观看| 中文亚洲av片在线观看爽| 精品国产美女av久久久久小说| 亚洲五月天丁香| 精品久久久久久成人av| 国产亚洲精品久久久久久毛片| 午夜免费观看网址| 亚洲色图 男人天堂 中文字幕| xxx96com| 老司机靠b影院| 亚洲精品美女久久久久99蜜臀| 桃红色精品国产亚洲av| 可以在线观看毛片的网站| 两个人的视频大全免费| 听说在线观看完整版免费高清| 久久久精品国产亚洲av高清涩受| 国产成+人综合+亚洲专区| 天天躁狠狠躁夜夜躁狠狠躁| 免费人成视频x8x8入口观看| 亚洲天堂国产精品一区在线| 亚洲一区二区三区色噜噜| 亚洲国产欧洲综合997久久,| 国产精品美女特级片免费视频播放器 | 中文在线观看免费www的网站 | 一进一出抽搐动态| 欧美乱色亚洲激情| 在线观看一区二区三区| 香蕉国产在线看| 国内精品久久久久精免费| 三级国产精品欧美在线观看 | 成人av在线播放网站| 精品国内亚洲2022精品成人| 亚洲精品一区av在线观看| 舔av片在线| 亚洲成a人片在线一区二区| 在线观看舔阴道视频| 2021天堂中文幕一二区在线观| 国产精品精品国产色婷婷| 国产69精品久久久久777片 | 久久婷婷人人爽人人干人人爱| 亚洲五月天丁香| 中文字幕最新亚洲高清| 12—13女人毛片做爰片一| 国产精品日韩av在线免费观看| 欧美日韩福利视频一区二区| 欧美乱色亚洲激情| 久久天堂一区二区三区四区| 可以在线观看的亚洲视频| 精品久久久久久久人妻蜜臀av| 欧美+亚洲+日韩+国产| 波多野结衣高清作品| 精品国产乱码久久久久久男人| 日韩av在线大香蕉| 久久午夜亚洲精品久久| 听说在线观看完整版免费高清| 中文亚洲av片在线观看爽| 久久久久久九九精品二区国产 | 最新美女视频免费是黄的| 动漫黄色视频在线观看| 最近视频中文字幕2019在线8| 最新在线观看一区二区三区| 欧美不卡视频在线免费观看 | 亚洲av中文字字幕乱码综合| 国产成人系列免费观看| 99riav亚洲国产免费| 久久国产精品人妻蜜桃| 99国产极品粉嫩在线观看| 俄罗斯特黄特色一大片| 国产av一区在线观看免费| 夜夜看夜夜爽夜夜摸| 五月玫瑰六月丁香| 免费在线观看亚洲国产| 激情在线观看视频在线高清| 亚洲国产欧洲综合997久久,| 久久久国产成人精品二区| 亚洲自偷自拍图片 自拍| 在线观看一区二区三区| 99在线视频只有这里精品首页| 亚洲精品av麻豆狂野| www.自偷自拍.com| 大型av网站在线播放| 国产片内射在线| 亚洲国产高清在线一区二区三| www.999成人在线观看| 可以在线观看的亚洲视频| 亚洲av成人一区二区三| 久久精品国产亚洲av香蕉五月| 日韩大码丰满熟妇| 一本精品99久久精品77| 日韩精品青青久久久久久| 极品教师在线免费播放| 日本在线视频免费播放| 精品久久久久久久久久免费视频| 亚洲精品一区av在线观看| 最近最新中文字幕大全免费视频| 日韩大尺度精品在线看网址| 最好的美女福利视频网| 久久精品91无色码中文字幕| 国产探花在线观看一区二区| 啦啦啦免费观看视频1| 十八禁人妻一区二区| 亚洲精品av麻豆狂野| 日韩成人在线观看一区二区三区| 91国产中文字幕| 亚洲在线自拍视频| 亚洲色图av天堂| 可以在线观看的亚洲视频| 久久久国产成人精品二区| 黄色丝袜av网址大全| 女人爽到高潮嗷嗷叫在线视频| 亚洲欧美精品综合一区二区三区| 亚洲精品在线观看二区| 天堂√8在线中文| 麻豆av在线久日| 最近在线观看免费完整版| 免费看日本二区| 久久久久免费精品人妻一区二区| 欧美黑人精品巨大| 国产成人av教育| 欧美精品啪啪一区二区三区| 国产精品九九99| 欧美黄色淫秽网站| 国产99白浆流出| 舔av片在线| √禁漫天堂资源中文www| 久久婷婷成人综合色麻豆| 听说在线观看完整版免费高清| svipshipincom国产片| 我的老师免费观看完整版| 黄色视频,在线免费观看| 欧美日韩亚洲国产一区二区在线观看| 久久久久久九九精品二区国产 | 久久久久免费精品人妻一区二区| 波多野结衣高清作品| 女人被狂操c到高潮| 日本成人三级电影网站| 国内毛片毛片毛片毛片毛片| 亚洲天堂国产精品一区在线| 亚洲成人中文字幕在线播放| 日韩有码中文字幕| 久久国产精品影院| 男女之事视频高清在线观看| 亚洲天堂国产精品一区在线| 啦啦啦免费观看视频1| 国产av又大| 久久精品亚洲精品国产色婷小说| 国产一区二区在线av高清观看| 欧美中文日本在线观看视频| 日本成人三级电影网站| 狠狠狠狠99中文字幕| 啦啦啦观看免费观看视频高清| 色在线成人网| bbb黄色大片| 国产精品国产高清国产av| 床上黄色一级片| 亚洲avbb在线观看| 婷婷精品国产亚洲av在线| 大型av网站在线播放| 欧美最黄视频在线播放免费| 亚洲激情在线av| 一级作爱视频免费观看| 精品少妇一区二区三区视频日本电影| 亚洲欧美一区二区三区黑人| 精品久久久久久久人妻蜜臀av| 久久精品aⅴ一区二区三区四区| 99精品久久久久人妻精品| 成人国产综合亚洲| 精品久久久久久久毛片微露脸| 国产精品永久免费网站| 亚洲成人精品中文字幕电影| 女警被强在线播放| 一级黄色大片毛片| 男女之事视频高清在线观看| 午夜日韩欧美国产| 哪里可以看免费的av片| 高清在线国产一区| 日韩 欧美 亚洲 中文字幕| 国产av又大| 成人高潮视频无遮挡免费网站| 十八禁网站免费在线| 亚洲第一欧美日韩一区二区三区| 不卡一级毛片| 久久精品91无色码中文字幕| 国内精品一区二区在线观看| 国产精品精品国产色婷婷| 国产精品一区二区免费欧美| 午夜a级毛片| 国产麻豆成人av免费视频| 777久久人妻少妇嫩草av网站| 亚洲av电影在线进入| www.精华液| 国产三级中文精品| 国产欧美日韩一区二区精品| 亚洲精品一卡2卡三卡4卡5卡| 成在线人永久免费视频| 日日夜夜操网爽| 黄色女人牲交| 色综合欧美亚洲国产小说| 久久精品人妻少妇| 香蕉国产在线看| 欧美不卡视频在线免费观看 | 婷婷精品国产亚洲av| or卡值多少钱| 日日夜夜操网爽| 国产精品久久久人人做人人爽| 久久久久性生活片| 成人av一区二区三区在线看| 俺也久久电影网| 不卡av一区二区三区| 日韩三级视频一区二区三区| 日本一本二区三区精品| 一进一出好大好爽视频| 婷婷丁香在线五月| 亚洲精品在线观看二区| 18禁黄网站禁片午夜丰满| 全区人妻精品视频| 久久天躁狠狠躁夜夜2o2o| 久久精品亚洲精品国产色婷小说| 亚洲人成77777在线视频| 91老司机精品| 色综合亚洲欧美另类图片| 狂野欧美激情性xxxx| 午夜福利高清视频| 国产av又大| av免费在线观看网站| 亚洲九九香蕉| 亚洲国产日韩欧美精品在线观看 | avwww免费| 97超级碰碰碰精品色视频在线观看| 三级国产精品欧美在线观看 | 中文字幕最新亚洲高清| 草草在线视频免费看| 国产区一区二久久| 人人妻人人澡欧美一区二区| 无人区码免费观看不卡| 免费在线观看影片大全网站| 一本一本综合久久| 国产精品久久久久久久电影 | 99国产综合亚洲精品| 一级毛片女人18水好多| 欧美黄色片欧美黄色片| 国产高清videossex| 亚洲国产精品sss在线观看| 三级毛片av免费| 妹子高潮喷水视频| 久久久久九九精品影院| 精品不卡国产一区二区三区| 中国美女看黄片| 免费在线观看亚洲国产| 亚洲精品中文字幕在线视频| 亚洲国产欧美一区二区综合| 少妇熟女aⅴ在线视频| 欧美性猛交黑人性爽| 99热这里只有是精品50| 亚洲成人国产一区在线观看| 国产高清videossex| 国产不卡一卡二| 黄色片一级片一级黄色片| 国产精品久久久久久久电影 | 我要搜黄色片| 国产精品亚洲美女久久久| 亚洲国产欧美人成| 一级毛片高清免费大全| 欧美日韩中文字幕国产精品一区二区三区| 午夜精品一区二区三区免费看| 日韩欧美一区二区三区在线观看| 日韩欧美在线二视频| 亚洲成人中文字幕在线播放| 特大巨黑吊av在线直播| 美女免费视频网站| 三级毛片av免费| 日韩欧美 国产精品| 十八禁人妻一区二区| 国产精品1区2区在线观看.| 成人午夜高清在线视频| 成人国产综合亚洲| 母亲3免费完整高清在线观看| 老司机深夜福利视频在线观看| 久久久精品欧美日韩精品| 99国产精品99久久久久| 欧美日韩中文字幕国产精品一区二区三区| 99国产精品99久久久久| 一个人免费在线观看的高清视频| netflix在线观看网站| 国产精品日韩av在线免费观看| 免费观看精品视频网站| 亚洲av成人av| 精品国内亚洲2022精品成人| 久久香蕉国产精品| 黄色毛片三级朝国网站| 欧美性猛交黑人性爽| 国产激情偷乱视频一区二区| 久久香蕉国产精品| 亚洲中文日韩欧美视频| 90打野战视频偷拍视频| netflix在线观看网站| 视频区欧美日本亚洲| 啦啦啦观看免费观看视频高清| 亚洲av美国av| 高潮久久久久久久久久久不卡| 国产精品免费一区二区三区在线| 精品久久久久久久久久免费视频| 长腿黑丝高跟| 日日摸夜夜添夜夜添小说| 99在线人妻在线中文字幕| 亚洲人成网站高清观看| 亚洲男人天堂网一区| 最新美女视频免费是黄的| 午夜免费观看网址| 国产在线精品亚洲第一网站| 国产91精品成人一区二区三区| 亚洲第一电影网av| 精品乱码久久久久久99久播| 怎么达到女性高潮| 琪琪午夜伦伦电影理论片6080| 久久 成人 亚洲| 国产一区二区激情短视频| 国产精品电影一区二区三区| 露出奶头的视频| 亚洲av片天天在线观看| 欧美日韩乱码在线| 天天一区二区日本电影三级| 亚洲黑人精品在线| 国产亚洲av高清不卡| a在线观看视频网站| 熟女电影av网| 99在线视频只有这里精品首页| 悠悠久久av| 1024手机看黄色片| 大型黄色视频在线免费观看| 亚洲成a人片在线一区二区| 国产亚洲精品第一综合不卡| 少妇的丰满在线观看| 亚洲国产精品999在线| 欧美3d第一页| www日本黄色视频网| 成人亚洲精品av一区二区| 国内揄拍国产精品人妻在线| 国产人伦9x9x在线观看| 国产成年人精品一区二区| 亚洲欧美日韩高清在线视频| 久久久久久久午夜电影| 久久精品国产综合久久久| 免费看美女性在线毛片视频| 曰老女人黄片| 嫁个100分男人电影在线观看| 欧美成人午夜精品| 禁无遮挡网站| 男人舔女人的私密视频| 成人国语在线视频| 草草在线视频免费看| 天堂影院成人在线观看| 亚洲熟妇中文字幕五十中出| 国产成人精品久久二区二区免费| 香蕉丝袜av| 国产亚洲精品av在线| 制服丝袜大香蕉在线| 亚洲国产精品合色在线| 18禁裸乳无遮挡免费网站照片| 精品国产亚洲在线| 日韩有码中文字幕| 亚洲成人精品中文字幕电影| √禁漫天堂资源中文www| 久久精品国产清高在天天线| 脱女人内裤的视频| 一个人免费在线观看的高清视频| 亚洲va日本ⅴa欧美va伊人久久| 亚洲av熟女| 国产乱人伦免费视频| 99riav亚洲国产免费| 日本黄大片高清| 午夜精品久久久久久毛片777| 伊人久久大香线蕉亚洲五| 两人在一起打扑克的视频| 天天躁狠狠躁夜夜躁狠狠躁| 成人18禁在线播放| 亚洲18禁久久av| 麻豆一二三区av精品| 俄罗斯特黄特色一大片| 午夜激情av网站| 亚洲精品久久国产高清桃花| 久久久久久久午夜电影| 欧美国产日韩亚洲一区| 99精品欧美一区二区三区四区| 国产精品一区二区免费欧美| 久久久国产精品麻豆| 久久精品亚洲精品国产色婷小说| 亚洲国产欧美一区二区综合| 色哟哟哟哟哟哟| 国产麻豆成人av免费视频| 村上凉子中文字幕在线| 蜜桃久久精品国产亚洲av| 亚洲激情在线av| 欧美最黄视频在线播放免费| 国内毛片毛片毛片毛片毛片| 一二三四在线观看免费中文在| 嫁个100分男人电影在线观看| 少妇粗大呻吟视频| 女人被狂操c到高潮| 亚洲美女视频黄频| 淫妇啪啪啪对白视频| 亚洲精品国产精品久久久不卡| 99久久99久久久精品蜜桃| 亚洲七黄色美女视频| 一级黄色大片毛片| 可以在线观看的亚洲视频| 身体一侧抽搐| 99riav亚洲国产免费| 亚洲人成网站高清观看| 人人妻人人看人人澡| 国产精品,欧美在线| 国产97色在线日韩免费| 大型黄色视频在线免费观看| 日本一二三区视频观看| 亚洲国产精品成人综合色| 久久久国产成人精品二区| 神马国产精品三级电影在线观看 | 欧美日韩国产亚洲二区| 嫩草影院精品99| 搡老熟女国产l中国老女人| 久久久国产精品麻豆| 成人精品一区二区免费| 久久久久久大精品| 色综合婷婷激情| 日韩欧美免费精品| 日本熟妇午夜| 51午夜福利影视在线观看| 久久精品国产综合久久久| 亚洲中文av在线| 国产精品一区二区免费欧美| 国产精品一区二区三区四区久久| 亚洲av成人精品一区久久| 日韩三级视频一区二区三区| 两个人免费观看高清视频| 成年女人毛片免费观看观看9| 精品人妻1区二区| 欧美日韩福利视频一区二区| 成人特级黄色片久久久久久久| 国模一区二区三区四区视频 | 国产乱人伦免费视频| 黄频高清免费视频| 国产成+人综合+亚洲专区| a级毛片a级免费在线| 精品久久久久久久人妻蜜臀av| 19禁男女啪啪无遮挡网站| 黄色a级毛片大全视频| 美女高潮喷水抽搐中文字幕| 欧美大码av| 国产精品免费一区二区三区在线| 精品久久久久久久久久久久久| av欧美777| 熟女少妇亚洲综合色aaa.| 99re在线观看精品视频| 91麻豆av在线| 国产精品久久久av美女十八| 可以免费在线观看a视频的电影网站| 亚洲成人精品中文字幕电影| 久久久久久亚洲精品国产蜜桃av| 亚洲av成人不卡在线观看播放网| x7x7x7水蜜桃| 婷婷精品国产亚洲av在线| 欧美3d第一页| 五月伊人婷婷丁香| 蜜桃久久精品国产亚洲av| 国产单亲对白刺激| 两个人看的免费小视频| 免费av毛片视频| 国产久久久一区二区三区| 他把我摸到了高潮在线观看| 亚洲人成网站高清观看| 变态另类丝袜制服| 黑人操中国人逼视频| 日韩欧美免费精品| 国产亚洲精品一区二区www| 国产精品精品国产色婷婷| 国产亚洲精品一区二区www| 亚洲一码二码三码区别大吗| 在线a可以看的网站| 久9热在线精品视频| av中文乱码字幕在线| 国内精品久久久久久久电影| 国产男靠女视频免费网站| 国产单亲对白刺激| 无遮挡黄片免费观看| 国产单亲对白刺激| 亚洲国产看品久久| 国产精品久久电影中文字幕| 国产高清激情床上av| 国产高清videossex| 丰满人妻一区二区三区视频av | 国产精品98久久久久久宅男小说| 麻豆av在线久日| 国产精品亚洲一级av第二区| 91国产中文字幕| 久久久久久免费高清国产稀缺| 好男人在线观看高清免费视频| 日本免费一区二区三区高清不卡| 18禁黄网站禁片午夜丰满| 成人国产一区最新在线观看| 日本撒尿小便嘘嘘汇集6| 亚洲美女黄片视频| 精品欧美一区二区三区在线| 哪里可以看免费的av片| 亚洲av五月六月丁香网| 午夜老司机福利片| 黄色女人牲交| 亚洲国产日韩欧美精品在线观看 | 亚洲欧美一区二区三区黑人| 两个人的视频大全免费| 欧美成人免费av一区二区三区| 床上黄色一级片| 国产精品99久久99久久久不卡| 午夜老司机福利片| 1024香蕉在线观看| 久久久久免费精品人妻一区二区| 亚洲成av人片免费观看| www日本黄色视频网| 黄色毛片三级朝国网站| 1024视频免费在线观看| 免费看a级黄色片| 91老司机精品| 亚洲aⅴ乱码一区二区在线播放 | 熟女少妇亚洲综合色aaa.| 久久精品综合一区二区三区| 黑人巨大精品欧美一区二区mp4| 国产视频内射| 波多野结衣高清作品| 手机成人av网站| 精品无人区乱码1区二区| 亚洲成人国产一区在线观看| 日韩国内少妇激情av| 99在线视频只有这里精品首页| 亚洲精品久久成人aⅴ小说| 一级毛片高清免费大全| 十八禁人妻一区二区| 97人妻精品一区二区三区麻豆| 成人欧美大片| 国模一区二区三区四区视频 | 国产高清有码在线观看视频 | 欧美乱妇无乱码| av有码第一页| 精品不卡国产一区二区三区| 久久精品国产99精品国产亚洲性色| 99在线人妻在线中文字幕| 国产精品1区2区在线观看.| 成年免费大片在线观看| 亚洲18禁久久av| 欧美日韩精品网址| 很黄的视频免费| 国产精品一区二区三区四区久久| 成年版毛片免费区| 国产亚洲欧美98| 在线永久观看黄色视频| 欧美乱色亚洲激情| 免费在线观看黄色视频的| 国产精品一及| 日韩国内少妇激情av| 亚洲人与动物交配视频| 日韩欧美三级三区| 白带黄色成豆腐渣| 亚洲免费av在线视频| 国产精品九九99| 夜夜看夜夜爽夜夜摸|